Experiments conducted in multiple models have shown that GSK3β can stabilize the β‐catenin complex, thus acting as a promoter of dysregulated cell differentiation; GSK3β could potentially even act as an enabler of chemoresistance, and its overexpression has been reported as a driver of drug resistance in some ovarian cancer samples [63, 64]. The gene discussed is GSK3B; the disease is ovarian carcinoma.